Bubendorf/Basel, June 10, 2011 – Bachem AG (SIX: BANB), the leading supplier of peptide active ingredients for the pharmaceutical and biotech industries, announced today that the integration of Sochinaz SA, Vionnaz, into Bachem AG, Bubendorf, would be successfully concluded as of June 30, 2011.
The plant in Vionnaz will operate as a branch of Bachem AG with the same line of products and services as before. Combining the organizational units of the two locations will produce synergies, particularly on the sales and marketing front and in research and development. The respective departments will each be placed under a common management structure. Further benefits will be achieved at the administrative level by sharing the same ERP system. No job cuts are foreseen. Currently about 100 employees are working at Vionnaz.
The above measures strengthen Bachem’s position to offer its customers a broad and well-diversified range of active ingredients. Furthermore, the “Quality Matters” label is a guarantee that the same high quality standards will be applied to products and services at all locations.
Dr. Rolf Nyfeler, CEO of Bachem Group:
“Having now completed the integration of Sochinaz and restructured our US operations last year, Bachem has put in place an efficient global organizational structure providing an excellent position to capture current and future growth opportunities.”
Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (API) as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.